Combined genetic polymorphism and risk for development of lung cancer

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 381, Issue 2, 1997, Pages 189-200

  El Zein, Randa ^a   Zwischenberger, Joseph B ^b   Wood, Thomas G ^b   Abdel Rahman, Sherif Z ^a   Brekelbaum, Chad ^b   Au, William W ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Cigarette smoking; CYP2D6; CYP2E1; Genetic polymorphism; GSTM1; GSTT1; Lung cancer; Molecular epidemiology

Indexed keywords

CYTOCHROME P450; DNA; GLUTATHIONE TRANSFERASE;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING;

ADULT; BIOTRANSFORMATION; CARCINOGENS; CASE-CONTROL STUDIES; COCARCINOGENESIS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; DISEASE SUSCEPTIBILITY; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC HETEROGENEITY; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; ISOENZYMES; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS; SMOKING; TEXAS;

NICOTIANA TABACUM;

EID: 0031589736     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(97)00166-8     Document Type: Article

References (59)

1. [1] J.F. Fraumeni Jr., Respiratory carcinogenesis: an epidemiologic appraisal, J. Natl. Cancer Inst. 55 (1975) 1039-1046.
2. [2] J.J. Mulvihill, Host factors in human lung tumors: an example of ecogenetics in oncology, J. Natl. Cancer Inst. 57 (1976) 3-7.
3. [3] T.A. Sellers, J.E. Bailey-Wilson, R.C. Elston, A.F. Wilson, G.Z. Elston, W.L. Ooi, H. Rotchild, Evidence of Mendelian inheritance in the pathogenesis of lung cancer, J. Natl. Cancer Inst. 82 (1990) 1272-1279.
4. [4] T.A. Sellers, J.D. Potter, J.E. Baily-Wilson, S.S. Rich, H. Rotschild, R.C. Elston, Lung cancer detection and prevention evidence for an interaction between smoking and genetic predisposition, Cancer Res. (Suppl.) 52 (1992) 2694s-2697s.
5. [5] C.C. Harris, Interindividual variation among humans in carcinogen metabolism, DNA adduct formation and DNA repair, Carcinogenesis 10 (1989) 1563-1566.
6. [6] H. Raunio, K. Husgufvel-Pursiainen, S. Anttila, E. Hietanen, A. Hirvonen, O. Pelkonen, Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility - a review, Gene 159 (1995) 113-121.
7. [7] F.J. Gonzalez, C.L. Crespi, H.V. Gelboin, DNA-expressed human cytochrome P450s: a new age of molecular toxicology and human risk assessment, Mutation Res. 247 (1991) 113-127.
8. [8] R. Ayesh, J.R. Idle, J.C. Ritchie, M.J. Crothers, M.R. Hetzel, Metabolic oxidation phenotypes as markers for susceptibility to lung cancer, Nature 311 (1984) 169-170.
9. [9] A.K. Daly, M. Armstrong, S.C. Monkman, M.E. Idle, J.R. Idle, Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes, Pharmacogenetics 1 (1991) 33-41.
10. [10] C.I. Crespi, B.W. Penman, H.V. Gelboin, F.J. Gonzales, A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1 butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6, Carcinogenesis 12 (1991) 1197-1201.
11. [11] F.P. Guengerich, D.H. Kim, M. Iwasaki, Role of cytochrome P450IIEI in the oxidation of many low molecular weight cancer suspects, Chem. Res. Toxicol. 4 (1991) 168-179.
12. [12] S. Hayashi, J. Watanabe, K. Kawajiri, Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIEI gene, J. Biochem. (Tokyo) 110 (1991) 559-565.
13. [13] F. Uematsu, H. Kikuchi, M. Motomiya, T. Abe, I. Sagami, T. Ohmachi, A. Wakui, R. Kanamaru, M. Watanabe, Association between restriction fragment length polymorphism of the human cytochrome P450IIEI gene and susceptibility to lung cancer, Jpn. J. Cancer Res. 82 (1991) 254-256.
14. [14] S. Kato, P.G. Shields, N.E. Caporaso, R.N. Hoover, B.F. Trump, H. Sugimura, A. Weston, C.C. Harris, Cytochrome P450IIEI genetic polymorphisms, racial variation, and lung cancer risk, Cancer Res. 52 (1992) 6712-6715.
15. [15] J. Seidegard, R.W. Pero, The hereditary transmission of high glutathione transferase activity towards trans-stilbene oxide in human mononuclear leucocytes, Hum. Genet. 69 (1985) 66-68.
16. [16] B. Mannervik, P. Alin, C. Guthenberg, H. Jensson, M.K. Tahir, M. Warholm, H. Jornvall, Identification of three classes of cytosolic glutathione transferase common to several mammalian species: correlation between structural data and enzymatic properties, Proc. Natl. Acad. Sci. USA 82 (1985) 7202-7206.
17. [17] J. Seidegard, W.R. Vorachek, R.W. Pero, W.R. Pearson, Hereditary differences in the expression of the human glutathione transferase active trans-stilbene oxide are due to a gene deletion, Proc. Natl. Acad. Sci. USA 85 (1988) 7293-7297.
18. [18] P.G. Board, Biochemical genetics of glutathione S-transferase, Am. J. Hum. Genet. 33 (1981) 36-43.
19. [19] D.A. Bell, C.L. Thompson, J.A. Taylor, C.R. Miller, F. Perera, L.L. Hsieh, G.W. Lucier, Genetic monitoring of human polymorphic cancer susceptibility genes by polymerase chain reaction: application to glutathione transferase μ, Environ. Health Perspect. 98 (1992) 113-117.
20. [20] J. Seidegard, R.W. Pero, D.G. Miller, E.J. Beattie, A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer, Carcinogenesis 7 (1986) 751-753.
21. [21] J. Seidegard, R.W. Pero, M. Markowittz, G. Rouch, D.G. Miller, E.J. Beattie, Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow up study, Carcinogenesis 11 (1990) 33-36.
22. [22] A. Hirvonen, K. Husgafvel-Pursianen, S. Antilla, H. Vainio, The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung, Carcinogenesis 14 (1993) 1479-1481.
23. [23] J.K. Wiencke, K.T. Kelsey, R.A. Lamela, W.A. Toscano, Human glutathione s-transferase deficiency as a marker of susceptibility to epoxide-induced cytogenetic damage, Cancer Res. 50 (1990) 1585-1590.
24. [24] H. Norppa, A. Hirvonen, H. Jarventaus, M. Uuskula, G. Tasa, A. Ojajarvi, M. Sorsa, Role of GSTT1 and GSTM1 genotypes in determining individual sensitivity to sister chromatid exchange induction by diepoxybutane in cultured human lymphocytes, Carcinogenesis 6 (1995) 1261-1264.
25. [25] C.M. Smith, K.T. Kelsey, J.K. Weincke, K. Leyden, S. Levin, D.C. Christiani, Inherited glutathione-s transferase deficiency is a risk factor for pulmonary asbestosis, Cancer Epidemiol. Biomarkers Prevent. 3 (1994) 471-477.
26. [26] D.A. Bell, J.A. Taylor, D.F. Paulson, C.N. Robertson, J.L. Mohler, G.W. Lucier, Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione s-transferase M1 (GSTM1) that increases the susceptibility to bladder cancer, J. Natl. Cancer Inst. 85 (1993) 1159-1164.
27. [27] S. Zhong, A.F. Howie, B. Ketterer, J. Taylor, J.D. Hayes, G.J. Beckett, G.G. Wathen, C.R. Wolf, N.K. Spurr, Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility, Carcinogenesis 12 (1991) 1533-1537.
28. [28] S.R. Heckbert, N.S. Weiss, D.L. Eaton, A.G. Motuklsky, Glutathione S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers, J. Natl. Cancer Inst. 84 (1992) 414-422.
29. [29] M. Kihara, M. Kihara, K. Noda, N. Okamoto, Increased risk of lung cancer in Japanese smokers with class mu glutathione S-transferase gene deficiency, Cancer Lett. 71 (1993) 151-155.
30. [30] S. Pemble, K.R. Schroeder, S.R. Spencer, D.J. Meyer, E. Hallier, H.M. Bolt, B. Ketterer, J.B. Taylor, Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism, Biochem. J. 300 (1994) 271-276.
31. [31] H.H. Nelson, J.K. Wiencke, D.C. Christiani, T.J. Cheng, Z.-F. Zuo, B.C. Schwartz, B.-K. Lee, M.R. Spitz, M. Wang, X. Xu, K.T. Kelsey, Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta, Carcinogenesis 16 (1995) 1243-1245.
32. [32] A.-K. Alexandrie, M.I. Sundberg, J. Seidegard, G. Tornling, A. Rannug, Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer type, Carcinogenesis 15 (1994) 1785-1790.
33. [33] J. Brokmöller, I. Cascorbi, R. Kerb, I. Roots, Combined analysis of inherited polymorphisms in arylamine N-acetyl-transferase 2, glutathione S-transferases Ml and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk, Cancer Res. 56 (1996) 3915-3925.
34. [34] J. Sambrook, E.F. Fritsch, T. Maniatis, in: Molecular Cloning a Laboratory Manual, 2nd ed., Cold Springs Harbor Laboratory Press, Cold Springs Harbor, NY, 1989, p. 9, 19-E.
35. [35] A.C. Cough, J.S. Miles, N.K. Spurr, J.E. Moss, A. Gaedigk, M. Eichelbaum, C.R. Wolf, Identification of the primary gene defect at the cytochrome P450 CYP2D6 locus, Nature 347 (1990) 773-776.
36. [36] M. Kagimoto, M. Heim, K. Kagimoto, T. Zeugin, U. Meyer, Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine, J. Biol. Chem. 265 (1990) 17209-17214.
37. [37] A. Gaedigk, M. Blum, R. Gaedigk, M. Eichelbaum, U.A. Meyer, Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of debrisoquine/sparteine polymorphism, Am. J. Hum. Genet. 48 (1991) 943-950.
38. 1934-A base change in intron 3 of a mutant CTP2D6 allele results in an aberrant 3′ splice recognition site, Am. J. Hum. Genet. 47 (1990) 994-1001.
39. [39] N. Spurr, A.C. Cough, D. Smith, R. Wolf, Genetic analysis of cytochrome P450 system, Methods Enzymol. 206 (1991) 149-166.
40. [40] W.A. Anwar, S.Z. Abdel-Rahman, R. El-Zein, H.M. Mostafa, W.W. Au, Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients, Carcinogenesis 17 (1996) 1923-1929.
41. [41] N.B. Breslow, N.B. Day, Statistical Methods in Cancer Research, Vol. I, International Agency for Research on Cancer, Lyon, 1980.
42. [42] U.A. Meyer, R.C. Skoda, U.M. Zanger, The genetic polymorphism of debrisoquine/sparteine metabolism - molecular mechanisms, Pharmacol. Ther. 46 (1990) 297-308.
43. [43] O. Pelkonen, D.D. Breimer, Role of environmental factors in the pharmacokinetics of drugs - considerations on animal models, P450 enzymes and probe drugs, in: P.G. Welling and L.P. Balant (Eds.), Handbook of Experimental Pharmacology, Pharmacokinetics of Drugs, Vol. 110, 1994, pp. 289-332.
44. [44] N. Caporaso, M.T. Landi, P. Vineis, Relevance of metabolic polymorphism to human carcinogenesis: evaluation of epidemiologic evidence, Pharmacogenetics 2 (1992) 4-19.
45. [45] A. Hirvonen, K. Husgafvel-Pursiainen, S. Anttila, A. Karjalainen, O. Pelkonen, H. Vainio, PCR-based CYP2D6 genotyping for Finnish lung cancer patients, Pharmacogenetics 3 (1993) 19-27.
46. [46] J.A.G. Agundez, C. Martinez, J.M. Ladero, M.C. Ledesma, J.M. Ramos, R. Martin, A. Rodriquez, C. Jara, J. Benitez, Debrisoquin oxidation genotype and susceptibility to lung cancer, Clin. Pharmacol. Ther. 55 (1994) 10-14.
47. [47] C. Bouchardy, S. Benhamou, P. Dayer, The effect of tobacco on lung cancer risk depends on CYP2D6 activity, Cancer Res. 56 (1996) 251-253.
48. [48] B.W. Penman, J. Reece, T. Smith, C.S. Yang, H.V. Gelboin, F.J. Gonzalez, C.L. Crespi, Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6, Pharmacogenetics 3 (1993) 28-39.
49. [49] A. Rannug, A.-K. Alexandrie, L. Persson, M. Ingelman-Sundberg, Genetic polymorphism of cytochrome P450 1A1, 2D6 and 2E1. Regulation and lexicological significance, J. Occup. Med. 37 (1995) 25-36.
50. [50] T. Tefre, A.K. Daly, M. Armstrong, J.B.S. Leathart, J.R. Idle, A. Brogger, A.-L. Borresen, Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls, Pharmacogenetics 4 (1994) 47-57.
51. [51] H. Bartsch, R. Montesano, Relevance of nitrosamines to human cancer, Carcinogenesis 5 (1984) 1381-1393.
52. [52] J.-S.H. Yoo, P.P. Guengerich, C.S. Yang, Metabolism of N-nitrosodialkylamines by human liver microsomes, Cancer Res. 48 (1988) 1499-1504.
53. [53] S.A. Wrighton, P.E. Thomas, D.E. Ryan, W. Levin, Purification and characterization of ethanol-inducible human hepatic cytochrome P-450HLj, Arch. Biochem. Biophys. 258 (1987) 292-297.
54. [54] R. El-Zein, J.B. Zwischenberger, S.Z. Abdel-Rahman, A.B. Sankar, W.W. Au, Polymorphism of metabolizing genes and lung cancer histology: prevalence of CYP2E1 in adenocarcinoma, Cancer lett. 112 (1997) 71-78.
55. [55] F.P. Guengerich, D.-H. Kim, M. Iwasaki, Role of human cytochrome P450 UE1 in the oxidation of many low molecular weight cancer suspects, Chem. Res. Toxicol. 4 (1991) 168-179.
56. [56] J. Brockmöller, R. Kreb, N. Drakoulis, M. Nitz, I. Roots, Genotype and phenotype of glutathione S-transferase class μ isoenzyme and Ψ in lung cancer patients and controls, Cancer Res. 53 (1993) 1004-1011.
57. [57] International Agency for Research on Cancer, The Relevance of N-nitroso Compounds to Human Cancer Exposures and Mechanisms, IARC Scientific Publication No. 84., IARC, Lyon, 1987, France.
58. [58] D.R. Shopland, H.J. Eyre, T.F. Pechacek, Smoking-attributable cancer mortality in 1991: is lung cancer now the leading cause of death among smokers in the United States?, J. Natl. Cancer Inst. 83 (1991) 1142-1148.
59. [59] N. Conforti-Froes, R. El-Zein, S.Z. Abdel-Rahman, J.B. Zwischenberger, W.W. Au, Predisposing genes and increased chromosome aberrations in lung cancer cigarette smokers, Mutation Res., in press.